Computed from SEC EDGAR filings and closing prices — not copied from any wealth ranking. Dataset . How we calculate this.
Disclosed holdings over time 53 weekly points
What the 1 currently disclosed position would have been worth at each week’s closing price. A rising line means the shares got more valuable, not that this person bought more.
How the line is built
Share counts are as last reported to the SEC and held constant; only prices move.
Insider activity Dec 16, 2024 – Mar 18, 2026
Christopher Van Tuyl is recorded in filings to the U.S. SEC via EDGAR as officer of the company, and reported 5 transactions between Dec 16, 2024 and Mar 18, 2026. The buy and sell totals below count only codes P, S.
Why the other codes are excluded
Share awards (A), shares withheld to pay tax (F), option exercises (M) and gifts (G) also appear in the table, but they are consequences of a pay package or a private transfer, not a decision to buy or sell on the open market. Counting them would turn this into a compensation ranking.
Reported transactions
Price 0.00 is a real reported figure on gifts (G) and share awards (A) — not a missing number. The 13 most recent rows are grouped into 10 lines by date, company and transaction type — open a line to see every lot with its own source link.
How to read this list
Every row is one line of one Form 4 or Form 5, with the filing it came from. Where the record carries no price at all we leave the cell empty instead of guessing one.
The shares and money on a grouped line add up only the lots listed inside that line, and only when every one of them carries the figure. Where a group mixes more than one reporting currency we leave the money blank rather than convert — no source publishes the rate that conversion would need.
-
Immunovant, Inc. IMVT S Open-market sale × 2 1,206 shares $47.7K
The 2 lots that make up this line, each with the source behind it. Shares Price Value Filing 63 $39.99 $2.5K SEC filing ↗ 1,143 $39.53 $45.2K SEC filing ↗ -
Immunovant, Inc. IMVT S Open-market sale × 2 17,824 shares $682.9K
The 2 lots that make up this line, each with the source behind it. Shares Price Value Filing 2,842 $38.96 $110.7K SEC filing ↗ 14,982 $38.19 $572.2K SEC filing ↗ -
Immunovant, Inc. IMVT M Option exercise or conversionnot a buy/sell decision 17,824 shares $270.9K at $15.20 SEC filing ↗
-
Immunovant, Inc. IMVT A Grant or awardnot a buy/sell decisionreported at zero 41,343 shares $0 at $0.00 SEC filing ↗
-
Immunovant, Inc. IMVT S Open-market sale × 2 10,813 shares $290.9K
The 2 lots that make up this line, each with the source behind it. Shares Price Value Filing 8,529 $26.78 $228.4K SEC filing ↗ 2,284 $27.38 $62.5K SEC filing ↗ -
Immunovant, Inc. IMVT A Grant or awardnot a buy/sell decisionreported at zero 50,787 shares $0 at $0.00 SEC filing ↗
-
Immunovant, Inc. IMVT A Grant or awardnot a buy/sell decisionreported at zero 109,956 shares $0 at $0.00 SEC filing ↗
Disclosed holdings
Shares is the amount on the form; value is that amount times the closing price shown. Rows with no closing price are left blank, so they may add up to less than the headline figure.
What is not counted here
Each row is one filing you can open. Private companies, real estate, bonds and crypto are not in SEC insider filings and are therefore not counted here.
| Issuer | Ticker | Security | Shares | Close | Value | Form | Reported | Filing |
|---|---|---|---|---|---|---|---|---|
| Immunovant, Inc. | IMVT | Common Stock | 147,053 | $39.25 | $5.8M | 4 | EDGAR ↗ |
Other insiders at the same companies
People who also file with the SEC at a company where Christopher Van Tuyl reports shares.
Sharing a filing does not mean they work together day to day — it means both names appear on the same issuer’s insider record.
- Andrew J Fromkin Board Member · Immunovant, Inc.
- Atul Pande Board Member · Immunovant, Inc.
- Douglas J Hughes Board Member · Immunovant, Inc.
- Eva Renee Barnett CFO · Immunovant, Inc.
-
Frank Torti
President · Immunovant, Inc.
- George V. Migausky Board Member · Immunovant, Inc.
- Jay S Stout CTO · Immunovant, Inc.
- Julia G Butchko Other Executive · Immunovant, Inc.
- Mark S Levine Other Executive · Immunovant, Inc.
- Melanie Gloria COO · Immunovant, Inc.
- Michael Geffner Other Executive · Immunovant, Inc.
- Peter Salzmann CEO · Immunovant, Inc.
Sources
The filings linked in the tables above are the sources for every figure on this page.
Think a number here is wrong? Open the linked filing and compare — how to report it.
Profile record last refreshed Sep 8, 2026.